Abstract
Background There are financial relationships between healthcare professionals and pharmaceutical companies, and these relationships have historically caused conflicts of interest and unduly influenced patient care. However, little was known about such relationship and its effect in clinical practice among specialists in respiratory medicine.
Methods Based on the retrospective analysis of payment data made available by all 92 pharmaceutical companies in Japan, this study evaluated the magnitude and trend of financial relationships between all board-certified Japanese respiratory specialists and pharmaceutical companies between 2016 and 2019. Magnitude and prevalence of payments for specialists were analyzed descriptively. The payment trends were assessed using the generalized estimating equations for the payment per specialist and the prevalence of specialists with payments.
Results Among all 7,114 respiratory specialists certified as of August, 2021, 4,413 (62.0%) received a total of USD($) 53,547,391 and 74,195 cases from 72 (78.3%) pharmaceutical companies between 2016 and 2019. The mean±SD and median (interquartile range) four-year combined payment values per specialist were $12,134±$34,045 and $2,210 ($715□$8,178) respectively. At maximum, one specialist received $495,332 personal payments over the four years. Both payments per specialist and prevalence of specialists with payments significantly increased during the four-year period, with 7.8% (95% CI: 5.5□9.8; p<0.001) in payments and 1.5% (95% CI: 0.61% □2.4%; p = 0.001) in prevalence of specialists with payments, respectively.
Conclusion Majority of respiratory specialists had increasingly received substantial personal payments from pharmaceutical companies for the reimbursement of lecturing, consulting, and writing between 2016 and 2019. These increasing financial relationships with pharmaceutical companies might cause conflicts of interest among respiratory physicians.
Competing Interest Statement
For financial conflicts of interest, Dr. Kusumi received personal fees from Otsuka Pharmaceutical Co. Ltd outside the scope of the submitted work. Dr. Saito received personal fees from TAIHO Pharmaceutical Co. Ltd outside the scope of the submitted work. Drs. Ozaki and Tanimoto received personal fees from Medical Network Systems outside the scope of the submitted work. Dr. Tanimoto also received personal fees from Bionics Co. Ltd, outside the scope of the submitted work. Regarding non-financial conflicts of interest among the study authors, all are engaged in ongoing research examining financial and non-financial conflicts of interest among healthcare professionals and pharmaceutical companies in Japan. Individually, Anju Murayama, Hiroaki Saito, Toyoaki Sawano, Tetsuya Tanimoto, and Akihiko Ozaki have contributed to several published studies addressing conflicts of interest and quality of evidence among clinical practice guideline authors in Japan and the United States. The other authors have no example conflicts of interest to disclose.
Funding Statement
This study was funded in part by the Medical Governance Research Institute. This non-profit research organization receives donations from a pharmaceutical company, Ain Pharmacies, and other organizations, and private individuals. This study also received support from Tansa, an independent non-profit news organization dedicated to investigative journalism.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of Interest Disclosures For financial conflicts of interest, Dr. Kusumi received personal fees from Otsuka Pharmaceutical Co. Ltd outside the scope of the submitted work. Dr. Saito received personal fees from TAIHO Pharmaceutical Co. Ltd outside the scope of the submitted work. Drs. Ozaki and Tanimoto received personal fees from Medical Network Systems outside the scope of the submitted work. Dr. Tanimoto also received personal fees from Bionics Co. Ltd, outside the scope of the submitted work. Regarding non-financial conflicts of interest among the study authors, all are engaged in ongoing research examining financial and non-financial conflicts of interest among healthcare professionals and pharmaceutical companies in Japan. Individually, Anju Murayama, Hiroaki Saito, Toyoaki Sawano, Tetsuya Tanimoto, and Akihiko Ozaki contributed to several published studies addressing conflicts of interest and quality of evidence among clinical practice guideline authors in Japan and the United States. The other authors have no example of conflicts of interest to disclose.
Funding/Support This study was funded in part by the Medical Governance Research Institute. This non-profit research organization received donations from a pharmaceutical company, Ain Pharmacies, other organizations, and private individuals. This study also received support from Tansa, an independent non-profit news organization dedicated to investigative journalism. None of the entities providing financial support for this study contributed to the design, execution, data analyses, interpretation of study findings, and manuscript drafting.
Data Availability
All data produced in the present study are available upon reasonable request to the authors